Abeona Therapeutics Inc.
ABEO
NASDAQ·Healthcare·Biotechnology·Mkt cap $339.1M
$5.91
▼ -0.67%
P/E
-5.35
Mkt Cap
$339.1M
52-Wk Range
$4.00–$7.65
52-Week Range
$4.00 - $7.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 14.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced AAV vector platform
- Focused rare disease expertise
- Innovative gene therapy technologies
- Strong clinical development pipeline
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Advancing clinical trial programs
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.9% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ABEO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 13, 2026
Reported EPS of -$0.35 vs -$0.23 consensus (-51.1% surprise). Revenue of $11.4M vs $12.2M expected (-7.0%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-51.1%
Revenue trend · last 8Q
—
—
—
—
—
—
—
+2745%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$400.0K
$0
$5.4M
$8.7M
$11.4M
Margins · last 8Q
Gross
63.3%
Operating
-120.0%
Profit
-177.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Oppenheimer · Aug 14, 2026
vs Industry
How ABEO stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related